logo
Gabon longs to cash in on sacred hallucinogenic remedy

Gabon longs to cash in on sacred hallucinogenic remedy

Yahoo10-05-2025
Beneath yellow fruit, hidden within the roots of the iboga plant in the forests of Gabon, lies a sacred treasure that the country is keen to make the most of.
For centuries, religious devotees have eaten it -- a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it "sacred wood". He consumes it in small amounts daily, he said, for his "mental and physical health".
"It has a lot of power to help human beings," added Stephen Windsor-Clive, a 68-year-old retiree.
"It's untapped. A mysterious force lies within this plant."
He travelled to Gabon from Britain and consumed iboga -- in a powder ground from its roots -- during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
- Economic potential -
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but "more and more effort is being made to domesticate the plant", said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have "anti-fatigue, antioxidant and anti-addictive" qualities.
Iboga, he believes, "is a potential lever to develop the economy and the whole country".
- Tradition and IP -
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects -- both helpful and harmful -- and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
"Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners," said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's "colossal therapeutic benefits", "Gabon is clearly missing out on the economic potential of iboga," he added.
"It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy."
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which "can produce ibogaine at unbeatable prices", said Guignon.
And "Gabonese traditional knowledge is not protected by intellectual property regulations."
Currently only one company in Gabon has a licence to export iboga products -- though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a "made in Gabon" certificate of origin for iboga.
"This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product," she said.
"Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists."
- Soothing properties -
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
"I definitely want to bring my daughter here and have her have the experience," he said.
"This is my last attempt to find something which might be of assistance to her."
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his "inner demons".
"I feel good in my body, in myself," he said, sitting under a tree after the ceremony.
"I feel like the iboga helped me to let go of things that you no longer need in your life."
lnf/emp/rlp/kjm/phz
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gambia baby death heightens alarm over female genital mutilation
Gambia baby death heightens alarm over female genital mutilation

News24

time7 hours ago

  • News24

Gambia baby death heightens alarm over female genital mutilation

A baby's death in The Gambia linked to female genital mutilation (FGM) has sparked outrage and calls for justice. FGM, illegal but prevalent in The Gambia, was linked to severe health risks and over 44 000 global deaths annually. The Gambia's Supreme Court is reviewing the 2015 FGM ban amidst pressure from religious traditionalists to overturn it. Rights activists in The Gambia are calling for justice after a one-month-old baby's death was linked to female genital mutilation, a widely practised but illegal procedure up for review before the country's Supreme Court. The Gambia has one of the highest rates of FGM in the world, with 73% of women and girls aged 15 to 49 having undergone the procedure, according to 2024 figures from UNICEF. The baby girl was pronounced dead upon arrival at a hospital in the capital, Banjul, after being 'allegedly subjected to circumcision' and developing severe bleeding, The Gambia Police Force said in a statement on Sunday. The death has sparked outrage among women's rights defenders working to combat the deeply rooted cultural and religious practice that they say is a harmful violation against women and girls. 'FGM is not a cultural tradition to be defended - it is a form of gender-based violence that can kill,' Santana Simiyu, a human rights lawyer with rights group Equality Now, said in a statement sent to AFP Tuesday. Police said two women allegedly involved in the case are in custody as an investigation is carried out in the western town of Wellingara, where the incident occurred. READ | Body parts found: Traditional healer linked to Gontse Makhubela's murder Researchers at Britain's University of Birmingham estimated in a study published in 2023 that approximately 44 320 girls and young women die each year due to FGM in the countries where it is practised. Former Gambian dictator Yahya Jammeh, now in exile, outlawed FGM in 2015, branding it outdated and not a requirement of Islam. Later that year, Parliament adopted the first law specifically banning the practice, which is now punishable by up to three years in prison but is rarely enforced. In July 2024, lawmakers revisited the matter, upholding the 2015 law despite pressure from religious traditionalists. But the ban was immediately challenged before the Gambian Supreme Court, where the petition remains pending. Simiyu said: If the Gambia's Supreme Court rules that the country's law prohibiting FGM is unconstitutional, it would have a hugely detrimental impact on the well-being of women and girls, leaving them without legal protections. FGM involves the partial or total removal of the female external genitalia or other injuries to the female genital organs. It can lead to serious health problems, including infections, bleeding, infertility and complications in childbirth.

Sanofi stops supply of high cholesterol drug to China due to limited availability
Sanofi stops supply of high cholesterol drug to China due to limited availability

Yahoo

time13 hours ago

  • Yahoo

Sanofi stops supply of high cholesterol drug to China due to limited availability

SHANGHAI (Reuters) -Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability. "The surge in demand has led to limited availability in China, and some other countries," Sanofi said in a statement sent to Reuters, adding "at the moment Praluent's supply in China has already stopped." It didn't say when supply would resume. Sanofi said it had "invested to strengthen global production of Praluent, to meet a rising global demand which accelerated sharply over the past two years". The company said clinical experts had found there were other medicines on China's National Reimbursement Drug List that were "safe and appropriate" for patients currently being treated with Praluent and it was working with healthcare providers in China to "ensure a smooth transition for patients". Sanofi is the latest foreign drugmaker to stop supplying popular medications to China. Merck suspended shipments of its blockbuster human papillomavirus vaccine Gardasil to the country in February, citing weak discretionary spending. Sign in to access your portfolio

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Yahoo

time13 hours ago

  • Yahoo

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the second quarter ended June 30, 2025. 'As clinical validation of the orexin agonist class continues to grow, we believe Centessa is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care. This includes not only restoring normal wakefulness to meet the real-world needs of individuals with sleep-wake disorders, but also potentially addressing comorbidities such as excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across a range of neurological, neurodegenerative and neuropsychiatric conditions where there is unmet need,' said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. Dr. Saha continued, 'ORX750, our most advanced OX2R agonist drug candidate, is progressing in an adaptive Phase 2a study that incorporates real-time drug development strategies aimed at optimizing dosing and best positioning ORX750 for planned registrational studies. This innovative approach continues to build our confidence in ORX750's potential to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH. Our top priority remains the successful execution of the Phase 2a study, and we look forward to sharing data for ORX750 in all three indications this year.' 'In parallel, we recently initiated clinical development of ORX142, our second OX2R agonist drug candidate, with data in acutely sleep-deprived healthy volunteers also expected this year. With two programs advancing toward key clinical milestones and a broad pipeline of potentially transformative orexin therapies, we believe Centessa is positioned to become a long-term leader in the orexin space,' concluded Dr. Saha. Recent Highlights Following clearance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) in June 2025, the Company initiated a Phase 1 first-in-human clinical trial of ORX142, with data in acutely sleep-deprived healthy volunteers expected this year. In April 2025, additional data from the Phase 1 study of ORX750 were presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting. Along with previously disclosed Phase 1 data, the poster highlighted time-course curves for both the Maintenance of Wakefulness Test (MWT) and the Karolinska Sleepiness Scale (KSS) from the 5.0 mg dose cohort. At this dose, sustained effects were observed across the full 8-hour post-dose observation period, with mean sleep latency exceeding 30 minutes on the MWT and improvements in KSS scores compared to placebo. An abstract highlighting the adaptive design of the Company's Phase 2a CRYSTAL-1 study for ORX750, including an open-label long-term extension (LTE), has been accepted as a poster presentation at the World Sleep 2025 Congress being held on September 5–10, 2025, in Singapore. The abstract, Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750 for Treatment of Patients with Narcolepsy (type 1 and 2) and Idiopathic Hypersomnia, is available on the conference website. A copy of the poster will be available on the Centessa website at at the time of the poster presentation. OX2R Agonist Pipeline and Anticipated Upcoming Milestones ORX750: The Phase 2a CRYSTAL-1 study is ongoing with data in NT1, NT2 and IH expected in 2025. ORX142: The Phase 1 first-in-human study of ORX142 is ongoing with data in acutely sleep-deprived healthy volunteers expected in 2025. ORX489: Currently in IND-enabling studies. Second Quarter 2025 Financial Results Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $404.1 million as of June 30, 2025. The Company expects its cash, cash equivalents and investments as of June 30, 2025 will fund operations into mid-2027. Research & Development (R&D) Expenses: R&D expenses were $42.7 million for the second quarter ended June 30, 2025, compared to $32.8 million for the second quarter ended June 30, 2024. General & Administrative (G&A) Expenses: G&A expenses were $11.9 million for the second quarter ended June 30, 2025, compared to $11.2 million for the second quarter ended June 30, 2024. Net Loss: Net loss was $50.3 million for the second quarter ended June 30, 2025, compared to $43.8 million for the second quarter ended June 30, 2024. About Centessa's Orexin Receptor 2 (OX2R) Agonist Program Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists represents a potential promising approach to address excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue associated with a broad range of neurological, neurodegenerative and neuropsychiatric disorders. Centessa is developing a pipeline of potential best-in-class OX2R agonists, including ORX750 for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), ORX142 for the treatment of select neurological and neurodegenerative disorders, and ORX489 for the treatment of neuropsychiatric disorders. ORX750 is being evaluated in the Phase 2a CRYSTAL-1 study. For more information, visit ORX750, ORX142 and ORX489 are investigational candidates and have not been approved by the FDA or any other regulatory authority. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of EDS, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit which does not form part of this release. Forward Looking Statements This press release contains forward-looking statements. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'seek,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company's ability to discover and develop transformational medicines for patients; its expectations for executing on the Company's pipeline; its expectations on its anticipated cash runway; the timing of commencement of new studies or clinical trials or clinical and preclinical data related to ORX750, ORX142, ORX489 and other OX2R agonist molecules; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing and anticipated studies or clinical trials of ORX750, ORX142, ORX489 and other OX2R agonist molecules; its expectations on executing its research and clinical development plans and the timing thereof; its expectations as to the potential results and impact of each of its clinical programs and trials; the Company's ability to differentiate ORX750, ORX142, ORX489 and other OX2R agonist molecules from other treatment options, including those being developed by competitors; the development, design and therapeutic potential of ORX750, ORX142, ORX489 and other OX2R agonist molecules, including the potential for ORX750 to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH; and regulatory matters, including the timing and likelihood of success of obtaining regulatory clearance or authorizations to initiate or continue clinical trials. Any forward-looking statements in this press release are based on our current expectations, estimates, assumptions and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to identify, screen and recruit a sufficient number of or any subjects in our existing and anticipated new studies or clinical trials of ORX750, ORX142, ORX489 or within anticipated timelines; our expectations relating to the clinical trials of ORX750 and ORX142, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and ORX142 and our ability to successfully conduct our clinical development of ORX750 and ORX142, our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; our operating costs and use of cash, including cash runway, cost of development activities and conducting clinical trials, future expenditures risks; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the historical results of preclinical studies or clinical studies will not be predictive of future results in ongoing or future studies; economic risks to the United States and United Kingdom banking systems; and geo-political risks such as the Russia-Ukraine war, the Middle East conflicts or trade wars and impact of the imposition of tariffs. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law. Contact: Kristen K. Sheppard, Esq. SVP of Investor Relations investors@ Centessa Pharmaceuticals plcConsolidated Statements of Operations and Comprehensive Loss(unaudited)(amounts in thousands except share and per share data) Three Months EndedJune 30, 2025 Three Months EndedJune 30, 2024 Six Months EndedJune 30, 2025 Six Months EndedJune 30, 2024 License and other revenue $ — $ — $ 15,000 $ — Operating expenses: Research and development 42,741 32,815 76,184 55,467 General and administrative 11,912 11,165 24,246 24,603 Loss from operations (54,653 ) (43,980 ) (85,430 ) (80,070 ) Interest and investment income 4,380 3,240 12,270 5,831 Interest expense (2,884 ) (2,525 ) (5,761 ) (5,054 ) Other non-operating income (expense), net 3,592 154 4,618 (1,383 ) Loss before income taxes (49,565 ) (43,111 ) (74,303 ) (80,676 ) Income tax expense 778 705 2,175 1,186 Net loss (50,343 ) (43,816 ) (76,478 ) (81,862 ) Other comprehensive (loss) income: Foreign currency translation adjustment (479 ) (61 ) 164 (86 ) Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax (5 ) 33 (2,786 ) 188 Other comprehensive (loss) income (484 ) (28 ) (2,622 ) 102 Total comprehensive loss $ (50,827 ) $ (43,844 ) $ (79,100 ) $ (81,760 ) Net loss per ordinary share - basic and diluted $ (0.38 ) $ (0.40 ) $ (0.57 ) $ (0.78 ) Weighted average ordinary shares outstanding - basic and diluted 133,677,405 109,489,184 133,354,373 104,688,452 Centessa Pharmaceuticals plcCondensed Consolidated Balance Sheets(unaudited)(amounts in thousands) June 30, 2025 December 31, 2024 Total assets: Cash and cash equivalents $ 44,242 $ 383,221 Investments in marketable securities 359,888 98,956 Other assets 87,997 94,621 Total assets $ 492,127 $ 576,798 Total liabilities Other liabilities $ 37,663 $ 66,313 Long term debt 109,545 108,940 Total liabilities 147,208 175,253 Total shareholders' equity 344,919 401,545 Total liabilities and shareholders' equity $ 492,127 $ 576,798 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store